Search Results
May 18, 2026, 20:00 ET Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
scleroderma related interstitial lung disease (SS-ILD). In preclinical studies，IBI3038 potently and synergistically inhibited IGF-1 and cis- as well as trans- IL-6 signaling superior to Teprotumumab. It robustly suppressed HA production by and proliferation of human lung and dermal fibroblasts. Besides,
More news about: Innovent Biologics
May 18, 2026, 14:22 ET B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy tissue. It correlates with poor prognosis. On paper, it has
More news about: USA News Group
May 18, 2026, 12:03 ET Galvanize Therapeutics Receives FDA Clearance for Aliya EX Generator, Expanding its Aliya Pulsed Electric Field Portfolio for Surgical Ablation of Soft Tissue
Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced that it received U.S. Food and Drug Administration 510(k) clearance for the Aliya® EX Generator
More news about: Galvanize Therapeutics, Inc.
May 18, 2026, 11:51 ET PFF Registry Soars Past 3,000 Enrollees for Lifesaving Research
participants, marking a major milestone in the effort to accelerate research into pulmonary fibrosis (PF) and interstitial lung disease (ILD), progressive and life-threatening lung diseases affecting more than 250,000 people in the United States. With more than 2,000 patients living with pulmonary fibrosis
More news about: The Pulmonary Fibrosis Foundation
May 18, 2026, 11:46 ET Decades of Neglect Leaves Millions of People with COPD at Risk--National COPD Leaders Call for Urgent Policy Action
year, with more than one in five patients readmitted within 30 days. Each flare-up of the disease causes permanent and cumulative harm to lung function, with studies showing that only 50% of people are alive within 3.6 years of their first severe exacerbation. Despite this burden, COPD remains
More news about: COPD Action Alliance
May 18, 2026, 10:30 ET Cancer Biomarkers Market worth $54.48 billion by 2032 | MarketsandMarkets™
for cancer biomarkers is divided into categories by cancer type: non-Hodgkin lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In 2025, the market for cancer biomarkers was dominated by the
More news about: MarketsandMarkets
May 18, 2026, 10:01 ET Telehealth Market Reach US$ 1,027.3 Bn by 2032 Expands Amid Digital Healthcare Adoption and Virtual Care Innovation | Persistence Market
Trials Market by Phase (Phase I, II, III, IV), Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), Cancer Type (Lung Cancer, Breast Cancer), and Regional Analysis, 2026 - 2033
More news about: Persistence Market Research Pvt. Ltd.
May 18, 2026, 08:00 ET Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.Pneumonitis/Interstitial lung disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated with PADCEV.When PADCEV was given in combination
More news about: Astellas Pharma Inc.
May 18, 2026, 01:26 ET AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer
breast cancer cases[1] and over 60% of new lung cancer diagnoses[2] occur in Asia. In breast cancer, almost half of Asian women present lower levels of HER2,[3] while TROP2 is present in 82–90% of non-small cell lung cancer.[4] Precise biomarker testing is hence
More news about: AstraZeneca
May 15, 2026, 17:49 ET Brayton Purcell LLP llama la atención sobre el informe de video principal y capital que destaca la mortal crisis de silicosis de piedra artificial entre los canteros de California
https://capitalandmain.com/the-lung-disease-thats-killing-california-stonecuttersCuando la piedra artificial de sílice cristalina, también conocida como piedra de ingeniería o fabricada,
More news about: Brayton Purcell LLP
May 15, 2026, 15:56 ET Brayton Purcell LLP Calls Attention to Capital & Main Video Report Highlighting Deadly Artificial Stone Silicosis Crisis Among California Stonecutters
The video, titled "The Lung Disease That's Killing California Stonecutters," documents the growing number of workers who have developed severe and irreversible lung disease after cutting and finishing artificial stone, a countertop material that
More news about: Brayton Purcell LLP
May 15, 2026, 08:30 ET Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
tumor‑agnostic indications.The program's impact spanned a broad range of solid tumors, including non‑small cell lung, breast, colorectal and pancreatic cancers, with non‑small cell lung cancer accounting for approximately 40% of identified opportunities. The study also underscored the importance of
More news about: Caris Life Sciences
May 15, 2026, 08:20 ET Pulmatrix Announces First Quarter 2026 Financial Results
technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates
More news about: Pulmatrix Inc.
May 15, 2026, 07:06 ET Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
indications, with a Phase 3 clinical program in acute myeloid leukemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and
More news about: Racura Oncology
May 14, 2026, 20:02 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
May 14, 2026, 19:03 ET SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
More news about: SN BioScience Inc
May 14, 2026, 17:16 ET PROCURE INTRODUCES NEW AWARENESS INITIATIVE TO EDUCATE PATIENTS ABOUT PROTON THERAPY
opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available,
More news about: ProCure Proton Therapy Center
May 14, 2026, 16:10 ET VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's
More news about: VolitionRx Limited
May 14, 2026, 15:48 ET Regal Global Entertainment Builds Strong Momentum in Q1 2026 with Market Share Gains and Enhanced Guest Experience on a Global Basis
guests.Regal also continued to lead in alternative and event-driven content. The company was the first major U.S. exhibitor to support Markiplier's Iron Lung, playing a key role in its $41M+ domestic box office achievement. International titles also delivered strong results, including Regal's highest-grossing
More news about: Regal Global Entertainment
May 14, 2026, 10:19 ET IMMP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: Faruqi & Faruqi, LLP
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted
More news about: Market News Updates
May 14, 2026, 08:00 ET Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program
More news about: Genprex, Inc.
May 14, 2026, 07:33 ET VARON Supports Asthma Awareness Month by Promoting Better Lung Health and Everyday Breathing Comfort
VARON, a leading provider of respiratory care solutions, is highlighting the importance of better lung health management and access to reliable oxygen support for individuals living with asthma and other respiratory conditions. Asthma Awareness
More news about: VARON
May 14, 2026, 07:06 ET VARON Celebrates Older Americans Month by Supporting Healthy Aging and Independence
choices such as light exercise, proper hydration, balanced nutrition, and regular medical checkups can significantly contribute to maintaining energy, lung health, and overall independence. VARON provides educational resources and guidance to complement these practices and help seniors optimize their quality
More news about: VARON
May 14, 2026, 05:29 ET "These Are So Tasty, I Look Forward To Having Them Every Day," Top 5 Gundry MD Mighty Reds Reviews 2026
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: Gundry MD